drugset / Trial / NCT04576104
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
Phase 2
Active not recruiting
51 enrolled
Northwestern University
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This phase II trial studies the effect of megestrol acetate alone or in combination with metformin in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer. Megestrol acetate is a drug used to block estrogen and suppress the effects of estrogen and androgens. It is the current non-surgical treatment of endometrial intraepithelial neoplasia. Metformin is a drug that has been found to have anti-cancer properties. Giving metformin and megestrol acetate together may decrease the growth of endometrial intraepithelial neoplasia in the uterus better than megestrol alone.
Timeline
- Start
- 2021-11-29
- Primary completion
- 2025-08-28
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Megestrol Acetate | Other / unclassified | — | Oral |
| Subject | Metformin | Small molecule | — | Oral |